NCT05242445View on ClinicalTrials.gov

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Cetrelimab

Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.

DRUG

Placebo

Placebo will be administered via SC injection or as an IV infusion.

Trial Locations (13)

2650

SGS Belgium NV, Edegem

2800

Az Sint-Maarten, Mechelen

30625

Medizinische Hochschule Hannover, Hanover

38043

CHU Grenoble, Grenoble

39008

Hosp. Univ. Marques de Valdecilla, Santander

41013

Hosp. Virgen Del Rocio, Seville

45147

Universitaetsklinikum Essen, Essen

46014

Hosp. Gral. Univ. Valencia, Valencia

75571

Hopital Saint-Antoine, Paris

80405

PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p., Gdansk

92110

Hopital Beaujon, Clichy

94010

APHP - Hopital Henri Mondor, Créteil

41-400

ID Clinic, Mysłowice

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY